Odonate Therapeutics, Inc. (ODT): Price and Financial Metrics


Odonate Therapeutics, Inc. (ODT): $3.78

0.01 (+0.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ODT Stock Price Chart Interactive Chart >

Price chart for ODT

ODT Price/Volume Stats

Current price $3.78 52-week high $11.62
Prev. close $3.77 52-week low $2.80
Day low $3.73 Volume 321,800
Day high $3.83 Avg. volume 3,279,939
50-day MA $3.41 Dividend yield N/A
200-day MA $4.10 Market Cap 145.56M

Odonate Therapeutics, Inc. (ODT) Company Bio


Odonate Therapeutics, LLC develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.


ODT Latest News Stream


Event/Time News Detail
Loading, please wait...

ODT Latest Social Stream


Loading social stream, please wait...

View Full ODT Social Stream

Latest ODT News From Around the Web

Below are the latest news stories about Odonate Therapeutics Inc that investors may wish to consider to help them evaluate ODT as an investment opportunity.

Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | April 8, 2021

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020.

Yahoo | February 23, 2021

Craig Johnson Is The Independent Director of Odonate Therapeutics, Inc. (NASDAQ:ODT) And Just Spent US$51k On Shares

Even if it's not a huge purchase, we think it was good to see that Craig Johnson, the Independent Director of Odonate...

Yahoo | January 2, 2021

Is ODT A Good Stock To Buy Now According To Hedge Funds?

Is Odonate Therapeutics, Inc. (NASDAQ:ODT) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

Yahoo | December 19, 2020

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia. “We are delighted to welcome Dr. Vacirca as a member of our Board of Directors, especially given his impressive leadership within the oncology community,” said Dr. Lan Huang, Founder and Chief Executive Officer of BeyondSpring. “In addition to his many years as an accomplish...

Yahoo | December 17, 2020

Read More 'ODT' Stories Here

ODT Price Returns

1-mo 26.42%
3-mo -21.13%
6-mo -2.23%
1-year -60.10%
3-year -43.65%
5-year N/A
YTD -21.25%
2020 -40.83%
2019 130.47%
2018 -43.68%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6893 seconds.